東陽光(600673.SH):擬以37.23億元出售東陽光藥股份合計4.524億股 將不再從事醫藥相關業務
格隆匯11月11日丨東陽光(600673.SH)公佈,上市公司擬向廣藥出售東陽光藥2.262億股內資股股份,向廣藥全資子公司香港東陽光出售東陽光藥2.262億股H股“全流通”股份。上述擬轉讓股份合計4.524億股,約佔東陽光藥總股本的51.41%。交易對方以現金方式支付全部交易對價。
經友好協商,綜合考慮標的資產評估情況、對應市值、歸屬於母公司股東淨資產、前次重組收購作價以及標的公司分紅情況,確定本次交易的4.524億股東陽光藥股份交易價格為37.23億元。
本次交易前,上市公司的主營業務包括電子新材料、合金材料、化工產品、醫藥製造。
通過本次交易,上市公司將不再從事醫藥相關產品的生產和銷售;公司將在夯實現有的“電子光箔-電極箔-鋁電解電容器”的一體化電子新材料產業鏈、空調熱交換器產業鏈和氯氟循環經濟產業鏈相關業務的基礎上,深化相關產業鏈上下游的整合,積極在變頻儲能、新能源汽車等新能源領域拓展新業務。
通過本次交易,一方面,公司可進一步將優勢資源集中於電子新材料等相關產業,減少在醫藥板塊轉型變革中面臨的不確定性;另一方面,公司可利用本次交易獲得的現金資產優化融資結構、改善財務狀況,降低公司整體的經營風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.